IMPORTANCE Electroconvulsive therapy (ECT) is a highly effective treatment for depression but is infrequently used owing to stigma, uncertainty about indications, adverse effects, and perceived high cost.
E lectroconvulsive therapy (ECT) is a highly effective treatment for depression. 1 Research indicates that ECT can be significantly more effective than pharmacotherapy, with 50% to 60% of patients achieving rapid remission of depression after a course of ECT compared with 10% to 40% with pharmacotherapy/psychotherapy. [2] [3] [4] Beyond its immediate clinical effects, ECT is also associated with decreased psychiatric hospitalization rates 5, 6 and reduced long-term risks of suicide and all-cause mortality. 7 Despite these benefits, ECT use remains low. A 2017 analysis found that only 1.5% of psychiatric inpatients with severe affective disorders received ECT while hospitalized, 5 and among individuals with depression in a large insurance claims database, fewer than 1% had ever received ECT. 8 Numerous explanations have been proposed for the infrequent use of ECT including stigma, adverse effects, and lack of access. 1, 5, 9 Although ECT can be a first-line treatment for depression with life-threatening psychotic or suicidal features, it is most often used in the United States for depression that has failed to respond to pharmacotherapy and/or psychotherapy.
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While treatment-resistant depression is a common indication for ECT, many clinical guidelines do not clearly specify how many pharmacotherapy/psychotherapy trials must fail before ECT is offered. 9, [12] [13] [14] In practice, patients often spend months to years with uncontrolled depression before considering ECT; in 1 US-based trial, patients averaged 38 weeks and 5 prior medication trials before initiating ECT. 15 Another issue that may limit use of ECT is its cost, estimated at $300 to $1000 per treatment. 16, 17 With5to15treat-ments per initial course and 10 to 20 maintenance treatments per year, the annual cost of ECT can exceed $10 000 vs several hundred dollars for many antidepressant medications.
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Amidst ongoing efforts to improve the value of US health care, it is critical to assess whether ECT confers a clinical benefit commensurate with its higher cost. Although prior studies have suggested that ECT for depression may be cost-effective in some health care systems, 19, 20 we are aware of no study that has reported the cost-effectiveness of ECT for treatmentresistant depression in the United States; furthermore, to our knowledge, no prior study has evaluated when in the course of depression treatment ECT should be offered.
To address these issues, we developed a decision analytic model to simulate the clinical and economic effects of ECT. Our analysis has 2 main objectives: (1) to quantify the costeffectiveness of ECT for treatment-resistant depression in the United States and (2) to define criteria for offering ECT that will maximize its health-economic value.
Methods

Overview of Analysis
We used a decision analytic model to assess the costeffectiveness of varying strategies for offering ECT to patients with major depressive disorder. Strategies are characterized by the number of prior treatment lines (defined as a unique combination of antidepressant medications and/or psychotherapy) 4 ,21 a patient must have tried before receiving ECT. We simulated 7 strategies: 1 strategy with no ECT available and 6 strategies with 0 to 5 lines prior to ECT. These strategies specifically target treatment-resistant depression because it is the most common indication for ECT in the United States. 12 Because the decision to offer ECT to patients with lifethreatening suicidality or psychosis relies on different costs, benefits, and clinical factors from those included in our model, we preferentially used data sources that do not target these indications. 12 However, because there is substantial overlap between psychosis, suicidality, and treatment-resistant depression, many of our data sources included some patients with psychotic or suicidal features.
22-24
We simulated the clinical and economic effects of these 7 strategies over a 4-year horizon. This horizon was chosen to allow adequate time for the costs and benefits of the various strategies to accrue while remaining within the range of prior modeling studies and long-term depression outcomes data. 25, 26 From these simulations, we calculated overall qualityadjusted life-years (QALYs, a measure combining longevity with health-related quality of life 27 ) and costs from a health care sector perspective.
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The incremental cost-effectiveness ratio (ICER) of each strategy was calculated as the ratio of its incremental cost (in 2013 US dollars) to its incremental benefit (in QALYs) relative to the next most effective nondominated strategy. A strategy is considered dominated if it is less effective and more costly than another strategy (strong dominance) or if it is less effective and would have a higher ICER than another strategy (extended dominance). 27 Commentators recommend using ICER thresholds ranging from $50 000 per QALY to $150 000 per QALY to define cost-effective health interventions in the United States 29, 30 ; for simplicity, we designated strategies with an ICER of $100 000 per QALY or less as cost-effective and also provided exact ICER values. In describing our model, analysis, and results, we adhered to the 2013 Consolidated Health Economic Evaluation Reporting Standards. 31 Because this was secondary research without use of any identifiable data, this study was not regulated by the University of Michigan Health Sciences institutional review board. For the same reason, no consent was obtained.
Key Points
Question What is the cost-effectiveness of electroconvulsive therapy compared with antidepressant medications and/or psychotherapy for treatment-resistant major depressive disorder in the United States?
Findings In this mathematical modeling analysis integrating data from multiple published sources, offering electroconvulsive therapy as third-line treatment for depression would cost an estimated $54 000 per quality-adjusted life-year gained. Over 4 years, this would reduce time with uncontrolled depression from 50% to 34% of life-years.
Meaning Electroconvulsive therapy may be an effective and cost-effective treatment for treatment-resistant depression and should be considered after failure of 2 or more lines of pharmacotherapy and/or psychotherapy.
Model Description
We developed a deterministic, state-transition model of depression treatment using Microsoft Excel 2016 ( Figure 1) ; its mathematical details are fully described in the eAppendix in the Supplement and summarized here. A simulated cohort of patients with major depressive disorder enters the model at initiation of first-line treatment and progresses through up to 9 treatment lines. Consistent with results of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial, 4 we do not explicitly distinguish between specific medications or between the presence/absence of psychotherapy. Instead, each change in treatment line represents switching between or augmenting the medications/psychotherapy used. Relapse rate after ECT was derived from 3 studies that are, to our knowledge, the only randomized trials of maintenance ECT plus pharmacotherapy vs pharmacotherapy alone; 6-month relapse rates in the ECT groups were 8%, 39 29%, 40 and 13%. 22 A weighted mean of these results yields a 6-month relapse probability of 16.8%, corresponding with an annual probability of 30.8%. We assumed all patients offered ECT would accept it (ie, we simulated exclusively ECT-willing patients). Although realworld uptake is substantially lower, this will not affect the costeffectiveness of ECT among those who do accept it; to confirm this, we varied uptake between 10% and 100% in sensitivity analysis.
Model Inputs
Cost and Utility Effects of ECT
Because recent, nationally representative cost data were lacking, we used a per-treatment ECT cost derived from a 1998 report by Bailine 45 updated to 2013 US dollars, yielding a value of $586. 50 We excluded inpatient care from the pertreatment ECT cost estimate because ECT is increasingly performed outpatient or initiated after a patient has already been hospitalized and hence would not cause increased inpatient length of stay; we also excluded the cost of psychiatric evaluations because these were already incorporated into our overall cost estimates. 5, 6 In sensitivity analysis, we varied this cost between $328 (reflecting per-treatment Centers for Medicare and Medicaid Services reimbursement to inpatient psychiatric facilities 5, 16 ) and $1000 (as estimated by an ECT specialist 17 ). We assumed that ECT use had no direct effect on background health care costs, but that it could affect these costs as mediated by enhanced remission/response of depression.
Based on multiple ECT trials, we simulated 8 ECT sessions during 1 month during the initial treatment course. 32 For maintenance treatment, we used a base-case value of 16 treatments per year, as reported in multiple maintenance ECT trials. 39, 55 In sensitivity analysis, we varied this between 7.1 treatments per year, 22 from a trial of adaptive maintenance ECT, to 24.9 treatments per year, for symmetry. We made the conservative assumption that the number of maintenance treatments in the first year applied to every subsequent year.
In sensitivity analysis, we assessed incorporating a direct utility decrement for patients receiving ECT (reflecting the possibility of a worse adverse event profile than background pharmacotherapy/psychotherapy 56 ) or a utility benefit (reflecting the faster clinical response and substantial utility increases observed in ECT trials 3, 57 ). For maintenance ECT, we varied this utility effect between −0.04 and 0.04 per month, from an estimate of the disutility associated with antidepressant medications. 41 Because adverse cognitive effects of ECT are predominantly observed in the first 15 days of treatment, 56 we tripled this range (−0.12 to 0.12) during the initial course.
Sensitivity and Uncertainty Analyses
To assess the robustness of our results to model input uncertainty, we performed univariate, probabilistic, and scenario sensitivity analyses. In univariate sensitivity analysis, we varied each individual model parameter over the ranges shown in Table 1 , and calculated cost-effectiveness outcomes at its upper and lower bounds.
In probabilistic sensitivity analysis, the model was run using parameter values drawn at random from distributions reflecting the uncertainty in the estimation of each parameter, ie, second-order uncertainty (Table 1) 
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; to estimate overall uncertainty, we repeated this process 10 000 times. For each run, the optimal strategy, defined as the strategy producing the most QALYs with ICER of $100 000 per QALY or less, is de- Table 1 are presented as the sum of the model's independent remission and response probabilities.
b In step 2 of the Sequenced Treatment Alternatives to Relieve Depression trial, slightly more patients met remission criteria than response criteria; hence, the independent response probability in the model is set to 0.
Cost termined. Prior research suggests that modeling probabilistic inputs independently may underestimate overall uncertainty.
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To address this, we performed 1 probabilistic sensitivity analysis with minimal parameter covariance (independent parameter variance), and 1 with maximal covariance (linked parameter variance); further details are provided in the eAppendix in the Supplement. Finally, in scenario sensitivity analysis, we assessed alternative approaches to modeling pharmacotherapy efficacy, depression cost, and maintenance ECT use. First, we assessed using first-line efficacy data from the previously described meta-analysis, 35 with subsequent response and remission probabilities calculated based on a 19% reduction in the odds of remission/response with each successive line. 60 Alternatively,
we assessed using only STAR*D efficacy data, without incorporating first-line efficacy data from the aforementioned meta-analysis. 4 ,35 Next, we used costs of depression derived from a study by Gibson et al. 8 This study is from 2010, rather than 2002 for our base-case data source, but uses a metric of prior treatment experience that is less analogous to lines in our model; annual costs range from $6916 to $15 576 for treatment lines 1 to 9. We next assessed incorporating an absolute mortality reduction of 0.07% for patients with remission/ response of depression, reflecting 1 estimate of the reduction in suicide mortality with effective treatment. 61 Finally, we simulated using maintenance ECT only after 1 relapse with maintenance pharmacotherapy alone; annual relapse probability with maintenance pharmacotherapy alone is set to 51.1%.
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Results
Model Validation
To provide external validation of our model, we compared model-generated outcomes with independent published results. During the 24 months after initiation of first-line antidepressant treatment, the model estimated an annual perpatient cost of $9413, compared with $9287 from a 2017 study of primarily privately insured patients 63 Base Case
Base case results are presented in Table 2 . Over 4 years, ECT was projected to reduce the fraction of time with nonresponse of depression from 50.2% of life-years to 37.1% to 32.9% of life-years, with greater reductions when ECT is offered earlier. These reductions translate to mean quality-adjusted survival gains of 0.12 to 0.15 QALYs, at incremental costs of $7300 to $12 000. Cost increases were attributable primarily to the cost of ECT; mean ECT-related cost increased from $9100 to $17 100 with earlier ECT offer, while the mean cost of other health care declined from $42 500 (without ECT) to $37 400 (with first-line ECT). Using a willingness-to-pay threshold of $100 000 per QALY, third-line ECT was projected to be cost-effective, with an ICER of $54 000 per QALY. Second-line and first-line ECT were not cost-effective, with ICERs of $564 000 per QALY and $815 000 per QALY. Analyzed incrementally, fourth-, fifth-, and sixthline ECT were all dominated (ie, they offered fewer QALYs at a worse ICER than other strategies). However, when compared with not offering ECT, each of these strategies would be cost-effective, with cost-effectiveness ratios between $60 000 to $70 000 per QALY.
Sensitivity and Uncertainty Analyses
Univariate sensitivity analysis results are shown in Figure 2 . Third-line ECT remained cost-effective (ICER ≤$100 000 per QALY) across all individual parameter variations. The cost of ECT was an important source of uncertainty, with annual maintenance cost and initial course cost both among the 4 parameters with the most influence over the ICER of third-line ECT (ICER ranges were $20 000 per QALY to $87 000 per QALY for maintenance cost and $41 000 per QALY to $74 000 per QALY for initial course cost). Extending beyond the preestablished In probabilistic sensitivity analysis, we found a 74% to 78% likelihood that at least 1 ECT strategy was cost-effective (ICER ≤$100 000/QALY) depending on the degree of parameter covariance ( Table 3) . Third-line ECT was the single optimal strategy in 56% to 58% of PSA simulations.
Finally, the 5 scenario sensitivity analyses (with alternative approaches to pharmacotherapy efficacy, depression cost, maintenance ECT use, and suicide) did not markedly change our results, with third-line ECT remaining cost-effective (ICER ≤$100 000/QALY) in all scenarios (eTable in the Supplement).
Discussion
We used a decision analytic model to evaluate the clinical and economic effects of varying strategies for using ECT to treat treatment-resistant depression in the United States. We found that ECT would substantially improve clinical outcomes, reducing time with uncontrolled depression from 50.2% to 32.9% to 37.1% of life-years over a 4-year horizon. We projected a 74% to 78% likelihood that ECT would be cost-effective in the United States given commonly accepted cost-effectiveness thresholds (ICER ≤$100 000 per QALY).
29 Across a range of realistic variations in model input data, we found that offering ECT after failure of 2 lines of pharmacotherapy/psychotherapy would most reliably maximize its health-economic value. For patients with 3 or more prior treatment trials, offering ECT later in the course of treatment would still be cost-effective. When compared with other depression interventions that have been evaluated, the cost-effectiveness of ECT for treatmentresistant depression is superior to pharmacogenetic testing 41 and similar to a rural collaborative care intervention.
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Based on these findings, we recommend that clinicians consider offering ECT to patients with major depressive disorder who have failed to respond to 2 trials of pharmacotherapy and/or psychotherapy. Notably, our findings align well with 2017 recommendations from Conway et al, who propose defining treatment-resistant depression by "failure of 2 adequate dose-duration antidepressants or psychotherapy from different classes" 21 and recommend considering ECT at this point. Similarly, the 2017 Florida best practice guidelines for treatment of major depressive disorder include ECT as a level 3 treatment, to be considered after failure of levels 1 and 2.
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Despite these recommendations, we recognize that many clinicians will regard offering ECT as third-line treatment to be overly aggressive, especially given the common view of ECT as a last-resort treatment for depression. 15, 69 To understand how third-line ECT can be reasonable and cost-effective, it is crucial to recognize how challenging treatment-resistant depression is to manage. Observational and trial data indicate that fewer than one-third of patients with this condition respond to pharmacotherapy and/or psychotherapy, and those who do respond are at high risk of relapse. 4, 70 Given the limited effectiveness of commonly used treatments, it may be less surprising that earlier ECT use would greatly improve clinical outcomes for patients with treatment-resistant depression.
Limitations
Our analysis has limitations related to the model's structure, the input data used, and the scope of the analysis. By necessity, a model must include some simplifying assumptions.
Where possible, we have chosen these assumptions to be conservative with respect to ECT's cost-effectiveness, such as assuming indefinite maintenance ECT use, excluding ECT's effects on mortality and speed of remission, 3, 7 and excluding the possibility of greater efficacy with earlier ECT use. 10 In addition, our model assumes that transition probabilities be- Table 1 provides parameter values. Parameters are arranged from those producing the greatest variation in the ICER (top) to those producing the least (bottom). QALY indicates quality-adjusted life-year. tween states (eg, relapse probabilities 71 ) do not vary over time. Despite these simplifications, the model's outcomes are well validated by independent data on costs, long-term clinical outcomes, and quality of life.
Cost-effectiveness of
Next, there are several shortcomings in our model's input data. Much of our cost data are more than a decade old and reflect primarily privately insured patients, [43] [44] [45] and there is uncertainty regarding the cost of ECT. 16, 17, 45 In addition, many of our estimates of relapse rates with pharmacotherapy or maintenance ECT reflect sample sizes of 100 patients or fewer. 4, 22, 39, 40 Finally, our reliance on clinical trial data may limit the generalizability and external validity of our results. 4 However, our main findings are robust to sensitivity analysis using alternative data sources or appropriately broad confidence intervals. Finally, the scope of our analysis introduces several limitations. Our choice of a health care sector perspective is intended to be relevant to patients, clinicians, and payers; however, this perspective excludes indirect costs and benefits such as patient transportation and productivity gains after depression treatment.
17,72 Additionally, we did not evaluate other novel interventions for treatment-resistant depression, such as repetitive transcranial magnetic stimulation or ketamine.
13,46
Conclusions
In this mathematical modeling analysis, we found that ECT is a cost-effective treatment option for treatment-resistant depression in the United States. Offering ECT after 2 failed lines of pharmacotherapy/psychotherapy is most likely to maximize its health-economic value and is concordant with recommendations from some national guidelines and ECT specialists. Increasing use of ECT by offering it earlier in the course of treatment-resistant depression could greatly improve outcomes for this difficult-to-treat patient population. 
Model states and transitions
We develop a deterministic Markov model with discrete one-month time-steps to simulate the treatment of major depressive disorder in the United States. The structure of the model is diagrammed in Figure 1 of the main text. The disease states within the model and transitions between them are described below.
Initiation
Upon starting a new line of treatment, simulated patients spend one time-step in the initiation state before the outcome of that treatment is determined. These states are denoted by I 1 for first-line initiation, I 2 for second-line initiation, etc. This state is intended to capture the delayed onset of treatment efficacy, as well as the time needed to ensure an adequate trial of a treatment before switching to a different treatment. [1] [2] [3] Remission, response, non-response
After spending one time-step in initiation, patients transition to one of three states intended to capture their acute response to treatment. Remission (R 1 , R 2 , etc.) indicates a near-complete resolution of depressive symptoms, as measured by one of several commonly-used rating scales; response (S 1 , S 2 , etc.) indicates ≥ 50% resolution of depressive symptoms; and non-response (F 1 , F 2 , etc.) indicates < 50% resolution of depressive symptoms. 4, 5 To determine the proportion of patients entering each outcome state, each line of treatment is characterized by a probability of remission, a, a probability of response, b, and a probability of non-response, 1 -a -b.
Relapse
Patients who have achieved remission or response on a given line of treatment may subsequently transition into the relapse state (E 1 , E 2 , etc.), reflecting a return of depressive symptoms. 4 Each line of treatment is characterized by a probability of relapse for those with initial remission, d R , and a probability of relapse for those with initial response, d S ; patients in remission (R) or response (S) are subject to these relapse probabilities during every model time-step. Those patients in the non-response (F) or relapse (E) states for treatment lines 1-8 transition to initiation (I) of the subsequent treatment line during the next model time-step.
Mortality and competing risks
The population of patients in the model is characterized by a probability of mortality per time-step, µ. Patients in all model states are subject to this mortality probability; for clarity, mortality probabilities are not shown in Figure 1 . As mortality is possible in any model state, patients in a given state are subject to competing risks; for example, a patient in remission on 1 st -line antidepressant treatment is subject to probabilities of death, relapse, and continued remission. To handle this, we treat mortality as an overriding risk; that is, only those patients who don't die in a time-step are subject to risks of relapse or other such transitions within the model.
Cost inflation
There are several nationally representative indices that can be used to inflate/deflate healthcare costs to a given year; in this analysis, we use an index called the medical care expenditure index (MCE). 6, 7 The MCE has two main benefits over other available indices. First, disease-specific inflation estimates are available, which show a different inflation rate for treatment of mental illness as compared with e.g. infectious diseases. Second, the MCE indices are designed to reflect changes in both unit costs and patterns of treatment for a given illness over time, rather than the change in price of a static bundle of goods and services.
Prior research has shown that, in the case of depression, using the MCE approach to evaluate inflation produces more conservative estimates of cost growth than other approaches do. 8 In our analysis, we find that our model's cost outcomes are well-validated by recent, independent data on overall costs of depression care, which lends support to the decision to use the more conservative MCE index.
Parameter covariance in probabilistic sensitivity analysis Probabilistic sensitivity analysis (PSA) produces an estimate of the aggregate uncertainty in a model's outcomes, given the individual uncertainty distributions surrounding each parameter within the model. Along with the uncertainty in each parameter's value, the covariance between parameters may be an important factor in determining overall uncertainty in outcomes. Prior research has shown that in some cases, treating probabilistic inputs as independent from one another may underestimate overall uncertainty. 9 To address this, we perform two separate PSAs. In the PSA with independent parameter variance, the value of each parameter is based on an independently drawn random variable between 0 and 1 applied to its probability distribution. In the PSA with linked parameter variance, a single random variable between 0 and 1 is drawn and applied in concert for every parameter within each of the following groups: depression costs for lines 1-9, initial remission and response probabilities for lines 1-9, relapse probabilities for lines 1-9, and initial and maintenance costs of ECT. The latter approach likely overestimates the degree of covariance between these parameters, but can help establish an upper bound on overall uncertainty.
